Newsfeeds - Spark Newswire

1 minute read

Myriad Genetics Q4 EPS $(0.02), Inline, Sales $160.80M Miss $163.40M Estimate

Today, 6:38 AM

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 93.55 percent increase over losses of $(0.31) per share from the same period last year.

MYGN

2 minute read

Myriad Genetics Highlights New Analysis Published In ‘Psychiatry Research’ For Co.’s GeneSight Test

By Benzinga Newsdesk

Today, 6:38 AM

Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder SALT LAKE CITY, Feb. 23, 2022 (GLOBE NEWSWIRE) --

MYGN

1 minute read

SVB Leerink Maintains Market Perform on Myriad Genetics, Lowers Price Target to $35

By Benzinga Newsdesk

Today, 6:38 AM

SVB Leerink analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and lowers the price target from $36 to $35.

MYGN

1 minute read

Myriad Genetics Q1 Adj. EPS $(0.02), Inline, Sales $167.30M Beat $165.04M Estimate

By Bill Haddad

Today, 6:38 AM

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 86.67 percent increase over losses of $(0.15) per share from the same period last year.

MYGN

4 minute read

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US

By Shanthi Rexaline

Today, 6:38 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AADI

19 minute read

Earnings Scheduled For November 2, 2021

By Benzinga Insights

Today, 6:38 AM

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.

7 minute read

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline

By Shanthi Rexaline

Today, 6:38 AM

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.

ADPT

2 minute read

Myriad Genetics Insider Sold Over $492K In Company Stock

By Benzinga Insights

Today, 6:38 AM

Nicole Lambert, Corporate Officer at Myriad Genetics (NASDAQ:MYGN), made a large insider sell on September 27, according to a new SEC filing.

MYGN

2 minute read

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

By Benzinga Newsdesk

Today, 6:38 AM

Illumina, Inc. (NASDAQ:ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the

ILMN

2 minute read

4 Stocks Insiders Are Buying

By Lisa Levin

Today, 6:38 AM

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

BHG